Martin Hils Zedira managing partner    Martin Hils was born on October 1st, 1967 in Rottweil, Germany.
He studied Technical Biology in Stuttgart and Molecular Biology in Paris-Orsay (France). In 1998 he obtained his PhD from the University of Stuttgart for his work on molecular evolution of a technical enzyme. After two years as postdoctoral researcher at the DaimlerChrysler Research Center (Ulm) he joined N Zyme BioTec (Darmstadt) as Head of R&D Molecular Genetics focusing on fibrinolytic enzymes and transglutaminases.
In 2007 he co-founded Zedira by a management buyout from N Zyme and holds the function of a CEO. The company specializes on therapeutic and diagnostic applications of transglutaminases.
  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • Transglutaminases in Medicine

      03.08.2017 - 05.08.2017
      Debrecen, Hungary

    • 15th Congress on Amino Acids, Peptides and Proteins

      07.08.2017 - 11.08.2017
      Vienna, Austria

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland